Published in Nat Rev Cancer on April 01, 2004
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn (2008) 2.71
Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn (2007) 2.35
S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. Sci Transl Med (2010) 2.13
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol (2009) 1.99
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer (2006) 1.84
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res (2010) 1.84
Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer (2006) 1.77
The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med (2013) 1.59
DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol (2013) 1.57
The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int (2015) 1.50
Molecular diagnostics of gliomas: state of the art. Acta Neuropathol (2010) 1.40
DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy. DNA Repair (Amst) (2007) 1.36
Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem (2010) 1.30
Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. Chem Res Toxicol (2011) 1.30
O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim Biophys Acta (2012) 1.22
Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome. Epigenetics (2011) 1.20
Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One (2012) 1.19
Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int (2014) 1.18
Integrating Epigenomics into Pharmacogenomic Studies. Pharmgenomics Pers Med (2008) 1.18
DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med Chem (2008) 1.17
MiR-221/222 target the DNA methyltransferase MGMT in glioma cells. PLoS One (2013) 1.16
Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. Front Oncol (2012) 1.14
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res (2012) 1.13
Current data and strategy in glioblastoma multiforme. J Med Life (2010) 1.11
The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS One (2011) 1.11
Metabolism and brain cancer. Clinics (Sao Paulo) (2011) 1.10
Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev (2009) 1.10
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncol (2009) 1.09
Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology (2011) 1.09
IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One (2013) 1.08
Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol (2015) 1.06
Targeting Aggressive Cancer Stem Cells in Glioblastoma. Front Oncol (2015) 1.05
EPMA position paper in cancer: current overview and future perspectives. EPMA J (2015) 1.04
Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results. PLoS One (2013) 1.04
New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. J Mol Histol (2006) 1.02
Rapid induction of chromatin-associated DNA mismatch repair proteins after MNNG treatment. DNA Repair (Amst) (2008) 1.01
The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma. Cell Mol Neurobiol (2011) 1.00
A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. Oncotarget (2014) 0.99
Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. Clinics (Sao Paulo) (2011) 0.99
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Oncotarget (2015) 0.98
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. Onco Targets Ther (2013) 0.97
Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics (2015) 0.96
Molecular epigenetics and genetics in neuro-oncology. Neurotherapeutics (2009) 0.95
Glioma virus therapies between bench and bedside. Neuro Oncol (2014) 0.95
Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. Core Evid (2010) 0.94
MethMarker: user-friendly design and optimization of gene-specific DNA methylation assays. Genome Biol (2009) 0.94
O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies. Mol Cancer (2007) 0.93
Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des (2009) 0.93
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. Br J Pharmacol (2013) 0.93
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol (2012) 0.92
Regulation of DNA repair by S-nitrosylation. Biochim Biophys Acta (2011) 0.92
Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection. DNA Repair (Amst) (2007) 0.92
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. BMC Cancer (2010) 0.92
Review of the alterations in DNA methylation in esophageal squamous cell carcinoma. Surg Today (2013) 0.92
Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer. Breast Cancer Res (2015) 0.91
O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions. Int J Mol Sci (2012) 0.91
Targeted deletion of GSNOR in hepatocytes of mice causes nitrosative inactivation of O6-alkylguanine-DNA alkyltransferase and increased sensitivity to genotoxic diethylnitrosamine. Carcinogenesis (2011) 0.91
Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities. Mutat Res (2013) 0.91
Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death Differ (2012) 0.90
Novel synthesis of O6-alkylguanine containing oligodeoxyribonucleotides as substrates for the human DNA repair protein, O6-methylguanine DNA methyltransferase (MGMT). Nucleic Acids Res (2006) 0.90
DNA repair modulates the vulnerability of the developing brain to alkylating agents. DNA Repair (Amst) (2009) 0.90
Syntheses and characterizations of the in vivo replicative bypass and mutagenic properties of the minor-groove O2-alkylthymidine lesions. Nucleic Acids Res (2014) 0.90
Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. DNA Repair (Amst) (2007) 0.90
O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. Br J Cancer (2005) 0.88
Targeting DNA repair pathways for cancer treatment: what's new? Future Oncol (2014) 0.87
Alkylation sensitivity screens reveal a conserved cross-species functionome. Mol Cancer Res (2012) 0.87
Direct detection and quantification of abasic sites for in vivo studies of DNA damage and repair. Nucl Med Biol (2009) 0.87
Role of MGMT as biomarker in colorectal cancer. World J Clin Cases (2014) 0.86
Predictive value of CHFR and MLH1 methylation in human gastric cancer. Gastric Cancer (2014) 0.86
Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients--yes, but how? Clin Neuropathol (2012) 0.86
Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature. Case Rep Oncol Med (2015) 0.85
Mass spectrometry for the assessment of the occurrence and biological consequences of DNA adducts. Chem Soc Rev (2015) 0.85
Prolonged cell cycle response of HeLa cells to low-level alkylation exposure. Cancer Res (2009) 0.85
"MGMT for pt mgmt": is methylguanine-DNA methyltransferase testing ready for patient management? J Mol Diagn (2008) 0.85
O6-methylguanine-DNA methyltransferase deficiency in developing brain: implications for brain tumorigenesis. DNA Repair (Amst) (2007) 0.84
High specificity of quantitative methylation-specific PCR analysis for MGMT promoter hypermethylation detection in gliomas. J Biomed Biotechnol (2009) 0.84
Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival. PLoS One (2013) 0.84
Assembly of the base excision repair complex on abasic DNA and role of adenomatous polyposis coli on its functional activity. Biochemistry (2011) 0.84
O6-Methylguanine DNA lesions induce an intra-S-phase arrest from which cells exit into apoptosis governed by early and late multi-pathway signaling network activation. Integr Biol (Camb) (2012) 0.84
KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O(6)-alkylguanine-DNA alkyltransferase in neoplastic cells. Biochem Pharmacol (2011) 0.84
Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype. Neuro Oncol (2013) 0.84
A rapid survival assay to measure drug-induced cytotoxicity and cell cycle effects. DNA Repair (Amst) (2011) 0.84
Toward a Molecular Classification of Colorectal Cancer: The Role of MGMT. Front Oncol (2013) 0.84
Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase. Biochem Pharmacol (2007) 0.83
Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations. PLoS One (2013) 0.83
Current available therapies and future directions in the treatment of malignant gliomas. Biologics (2009) 0.83
Heterogeneous DNA methylation contributes to tumorigenesis through inducing the loss of coexpression connectivity in colorectal cancer. Genes Chromosomes Cancer (2014) 0.83
Molecular neuropathology of gliomas. Int J Mol Sci (2009) 0.83
Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. Mol Cancer (2010) 0.83
Methylation of MGMT and ADAMTS14 in normal colon MUCOSA: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans. Oncotarget (2015) 0.83
MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. J Neurooncol (2010) 0.83
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer (2013) 0.82
Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2'-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine. J Med Chem (2007) 0.82
A distinct epigenetic signature at targets of a leukemia protein. BMC Genomics (2007) 0.82
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer (2011) 0.82
Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era. Oncotarget (2014) 0.81
S-nitrosoglutathione reductase deficiency increases mutagenesis from alkylation in mouse liver. Carcinogenesis (2013) 0.81